What is it about?
Antibody drug conjugates represent a new class of anticancer drugs that are either clinically approved or undergoing clinical trials in many types of malignancies. As the name indicates, these agents link an antitumor drug to an antibody that recognizes a specific target on or in the tumor cell. Our studies relate to Sacituzumab-govitecan, an antibody drug conjugate that is approved for certain forms of breast cancer. We determined that this agent promotes a form of growth arrest known as senescence in different experimental cancer models (breast, prostate, colorectal, ovarian and lung).
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This is only the second paper in the entire scientific literature that identifies senescence as an outcome of exposure to an antibody drug conjugate. The importance of this finding is that senescence may represent a mechanism whereby the tumor cell avoids cell death and lives on in a dormant state, only to eventually recover and contribute to recurrent disease. These studies also open up the possibility of utilizing drugs that specifically kill senescent tumor cells in combination with antibody drug conjugates.
Read the Original
This page is a summary of: Promotion of tumor cell senescence by the antibody–drug conjugate, sacituzumab govitecan, Molecular Pharmacology, September 2026, Elsevier,
DOI: 10.1016/j.molpha.2026.100142.
You can read the full text:
Contributors
The following have contributed to this page
